MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2019 International Congress

    Olfactory Hallucinations Induced by Pramipexole Treatment in Parkinson’s Disease

    G. Hatipoglu, S. Ozkaynak (Antalya, Turkey)

    Objective: In the treatment of Parkinson’s disease, dopamine agonists are among the preferred treatment options, particularly in the treatment of young Parkinson’s patients. The known…
  • 2019 International Congress

    Formulations and evaluations of Intranasal Nose to Brain Delivery of Curcumin with resveratrol Nanoparticle for treatment of Parkisonism

    A. Jain, S. Jain (Sagar, India)

    Objective: Parkinson’s disease (PD) is a common neurodegenerative disease characterized by motor symptoms of tremor, rigidity, bradykinesia, and postural instability. Growing evidence indicates that resveratrol…
  • 2019 International Congress

    Efficacy of opicapone in Parkinson’s disease patients according to baseline pramipexole use: a post-hoc analysis from combined BIPARK-I and II.

    A. Lees, J. Ferreira, O. Rascol, W. Poewe, F. Stocchi, A. Santos, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

    Objective: To evaluate opicapone’s (OPC) efficacy in levodopa-treated Parkinson’s Disease (PD) patients with or without concurrent pramipexole use (CPU). Background: OPC, a once-daily COMT inhibitor,…
  • 2019 International Congress

    Path to Prevention (P2P) – Developing a Prodromal PD Progression Biomarker Program

    K. Marek, A. Siderowf, C. Coffey, T. Foroud, V. Arnedo, E. Flagg, S. Chowdhury, K. Kieburtz, L. Chahine, J. Seibyl (New Haven, CT, USA)

    Objective: The overall objective of the Path to Prevention (P2P) initiative is to identify clinical, imaging, and biologic markers of progression during the prodromal phase…
  • 2019 International Congress

    A pilot study of the feasibility and effects of table tennis training in Parkinson’s Disease

    K. Olsson, A. Johansson, E. Franzén (Stockholm, Sweden)

    Objective: To investigate the feasibility and effects of table tennis training on balance control and physical function in individuals with Parkinson’s disease (PD). Background: Postural…
  • 2019 International Congress

    Unilateral delivery of cell-based therapy to the putamen and substantia nigra in patients with Parkinson’s disease who have an existing DBS system

    J. Quintero, J. Slevin, Z. Guduru, J. Gurwell, G. Gerhardt, C. van Horne (Lexington, KY, USA)

    Objective: Evaluate the safety and feasibility of unilateral cell-based therapy delivery to the putamen and substantia nigra in patients with Parkinson’s disease (PD) undergoing deep…
  • 2019 International Congress

    Safety of Bone marrow-derived Allogeneic Mesenchymal Stem Cells in Parkinson’s disease Patients

    M. Schiess, J. Suescun, T. Ellmore, MF. Doursout, E. Furr -Stimming, Z. Mei, A. Gee (Houston, TX, USA)

    Objective: Prove safety and tolerability of allogeneic mesenchymal stem cells (MSC) purified from bone marrow derived from a healthy adult and delivered intravenously in escalated…
  • 2019 International Congress

    Short term use of bromocriptine for treatment of Parkinson’s disease during pregnancy

    D. Taylor, P. Lewitt (West Bloomfield, MI, USA)

    Objective: Few reports describe experience with treatment of Parkinson's disease [PD] during pregnancy. About 5% of the population with PD are young onset (onset prior…
  • 2019 International Congress

    Impact of oral COMT-inhibitors on gut microbiota and biologically active microbial metabolites in patients with Parkinson’s Disease

    D. Grün, V. Zimmer, J. Kauffmann, M. Unger, J. Spiegel, KU. Dillmann, A. Schwiertz, K. Faßbender, M. Fousse (Homburg, Germany)

    Objective: To investigate if we were able to reproduce our previous findings in an independent patient cohort and whether such a correlation also exists in…
  • 2019 International Congress

    A descriptive study with molecular and cytogenetic analysis in patients of ataxia telangiectasia(AT) from the Indian subcontinent

    S. Das, S. Danda, M. Thomas, S. Yoganathan, V. Srivastava, S. Cleave A, A. Barney (Vellore, India)

    Objective: To characterize the clinical and radiological phenotype in patients with AT and correlate with the genetic analysis. Background: AT is a rare autosomal recessive…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 217
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley